Rafferty Asset Management
AXDX

Rafferty Asset Management’s Accelerate Diagnostics AXDX Stock Holding History

Rafferty Asset Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-24,149
Closed -$348K – 1139
2022
Q1 		$348K Sell
24,149
-3,182
-12% -$90.6K ﹤0.01% 1079
2021
Q4 		$1.43M Buy
27,331
+10,009
+58% +$557K 0.01% 770
2021
Q3 		$1.01M Sell
17,322
-1,828
-10% -$119K 0.01% 816
2021
Q2 		$1.54M Sell
19,150
-13,805
-42% -$1.1M 0.01% 752
2021
Q1 		$2.74M Buy
32,955
+28,197
+593% +$2.86M 0.02% 543
2020
Q4 		$361K Buy
+4,758
New +$426K ﹤0.01% 763

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Rafferty Asset Management's AXDX Position: Q2 2022 in Review

Rafferty Asset Management sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 24,149 shares — an estimated $348K sold.

Rafferty Asset Management first reported a position in AXDX in Q4 2020 and held it in 6 quarters. The position peaked at $2.74M in Q1 2021. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

  • Rafferty Asset Management reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 24,149 Accelerate Diagnostics shares in Q2 2022, an estimated $348K.
  • Rafferty Asset Management first reported a position in Accelerate Diagnostics in Q4 2020 and held it in 6 quarters.
  • Rafferty Asset Management's Accelerate Diagnostics position peaked at $2.74M in Q1 2021.
  • 74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on Rafferty Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.